Publication of List of Manufacturers Granted Licence for the Manufacture of Therapeutic Goods

Overview

The Therapeutic Goods Act 1989 was enacted to regulate the provision of therapeutic goods in Australia, ensuring that these products are safe, of high quality, and perform as claimed. This Act addresses the need for stringent oversight and regulation of therapeutic goods, including medicines, medical devices, and blood products, to protect public health. The Therapeutic Goods Administration, which operates under the auspices of the Department of Health, is the body responsible for administering this Act. One of the key policy objectives of the Act is to ensure that therapeutic goods are only supplied if they meet acceptable standards of quality and performance, thereby safeguarding the health and safety of consumers. On 2 April 2020, Katherine Clark, acting as the Delegate of the Secretary of the Department of Health, published a notice under section 38 of the Therapeutic Goods Act 1989. This notice informs the public that a licence to manufacture therapeutic goods has been granted to Delta Laboratories Pty Ltd. The licence, identified as MI-2017-LI-11602-1, authorises the company, located at 9 Chivers Road, Somersby, NSW, 2250, to manufacture therapeutic goods, ensuring they comply with the regulatory standards set forth by the Therapeutic Goods Administration.

Scope and Application

The Therapeutic Goods Act 1989 applies to any person or entity engaged in the manufacture, supply, or importation of therapeutic goods within Australia. The Act covers a broad spectrum of therapeutic goods, including medicines, medical devices, blood, and tissues, ensuring that these products meet necessary safety, quality, and efficacy standards. The Act applies nationally, covering the entire Commonwealth of Australia, and includes provisions that extend through subordinate legislation to provide detailed regulations and standards that must be adhered to by manufacturers, suppliers, and importers of therapeutic goods. Certain entities and activities may be exempt from specific requirements under the Act, such as those covered by exemptions under the Regulations, which can include low-risk products or small-scale manufacturing operations that meet specified criteria. The Act also incorporates mechanisms for the issuance of licences to manufacturers, as evidenced by the grant of a Licence to Manufacture Therapeutic Goods to Delta Laboratories Pty Ltd, ensuring that such manufacturers meet the regulatory standards set out by the Therapeutic Goods Administration.

Key Provisions

The key provisions of the Therapeutic Goods Act 1989 as presented in the Gazette (C2020G00285) relate to the publication of the list of manufacturers granted a licence to manufacture therapeutic goods. Specifically, section 38 of the Act provides the authority for the Secretary of the Department of Health, Therapeutic Goods Administration, to issue notices of such grants. In this instance, the Secretary, through the Delegate, Katherine Clark, has published a notice that Delta Laboratories Pty Ltd has been granted a Licence to Manufacture Therapeutic Goods under Licence No MI-2017-LI-11602-1. This licence is effective at the address 9 Chivers Road, Somersby, NSW, 2250. The Act imposes certain obligations and requirements on entities granted such a licence. These obligations include adherence to the standards and guidelines set forth by the Therapeutic Goods Administration. The licensed entity, Delta Laboratories Pty Ltd, must ensure that the therapeutic goods they manufacture comply with the stipulated quality, safety, and efficacy requirements. This encompasses maintaining appropriate records, conducting regular self-inspections, and reporting any adverse events or defects associated with their products. Furthermore, the entity must be prepared for inspections by the Therapeutic Goods Administration to verify compliance with the legislative standards. Failure to comply with the provisions of the Therapeutic Goods Act 1989 can lead to serious consequences. The Act provides for both civil and criminal penalties for breaches. Civil penalties can include fines up to a significant amount determined by the courts, depending on the severity and frequency of the breach. Criminal penalties may also apply, resulting in fines or imprisonment, or both, if the breach is deemed to be of a serious nature. The maximum penalties are outlined in the Act and can vary based on the specific provisions violated. The enforcement of these penalties is aimed at ensuring that manufacturers maintain high standards of quality and safety in the production of therapeutic goods.